Genetically engineered insulin: five years of experience.
Genetically engineered insulin: five years of experience.
复制标题
基因工程胰岛素：五年经验。
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
D. Pâris
中科院分区：
文献类型：
--
作者：
J. Brogard;J. Blicklé;D. Pâris
基因工程胰岛素是DNA重组技术的首次应用，已进入工业化生产并广泛应用于临床。首次临床试验四年后，似乎与纯化猪肉胰岛素只有微小的药代动力学差异；特别是，常规形式和 NPH 形式的皮下吸收更快。基因工程胰岛素的降血糖效力与纯化猪肉胰岛素相同，但据报道对反调节激素的作用较弱。然而，生物合成人胰岛素的主要优点是其物种特异性，这降低了其免疫原性。尽管生物合成人胰岛素确实具有一些免疫学特性并与牛肉或猪肉胰岛素抗体发生交叉反应，但在患有胰岛素抵抗或过敏等胰岛素产生的不良反应的患者中获得了令人信服的结果。
Genetically engineered insulin is the first application of recombinant DNA technology which has gone into industrial production and wide clinical use. Four years after the first clinical trials, it appears that there are only minor pharmacokinetic differences from purified pork insulin; in particular, a faster subcutaneous absorption for both regular and NPH forms. The hypoglycaemic potency of genetically engineered insulin is identical to that of purified pork insulin but a weaker effect on counterregulatory hormones has been reported. However, the main advantage of biosynthetic human insulin is its species specificity, which reduces its immunogenicity. Convincing results were obtained in patients suffering from insulin-produced adverse reactions such as insulin resistance or allergy, although biosynthetic human insulin does have some immunological properties and crossreacts with beef or pork insulin antibodies.